MEDICINOVA INC entered into Sales Agreement with Lucid Capital Markets, LLC valued at $50,000,000 (effective 2025-12-29).
“On December 29, 2025, MediciNova, Inc. (the “Company”) entered into an equity distribution agreement with Lucid Capital Markets, LLC (“Agent”) to sell shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), from time to time through the Agent, acting as sales agent, having a maximum aggregate offering price of $50,000,000 (the “Sales Agreement”).”
Geoffrey O'Brien resigned as Vice President at MEDICINOVA INC.
“On March 26, 2024, Geoffrey O’Brien informed MediciNova, Inc. (the “Company”) of his decision to retire from full-time employment and resign from his employment with the Company, effective as of April 2, 2024.”
Nicole Lemerond was appointed as Member of the Board at MEDICINOVA INC.
“On August 4, 2023, the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) appointed Nicole Lemerond as a member of the Board, effective immediately, filling an existing vacancy on the Board.”
Listing & Compliance Notices
MEDICINOVA INC received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(b)(1)).
“June 15, 2023, MediciNova, Inc. (the “Company”) received a letter (the “Audit Committee Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, due to Jeff Himawan, Ph.D. not standing for re-election as a Class I director of the Company at the Company’s 2023 annual meeting of stockholders held on June 13, 2023 (the “Annual Meeting”), the Company was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the “Audit Committee Listing Rule”), which requires the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of the Company to be co”
Shareholder Votes
MEDICINOVA INC shareholders approved Approve the Company’s 2023 Equity Incentive Plan, as disclosed in the Proxy Statement. at the 2023-06-13 meeting.
“To approve the Company’s 2023 Equity Incentive Plan, as disclosed in the Proxy Statement. This proposal was approved, with the votes thereon at the Annual Meeting as follows: Final Voting Results For Against Abstain Broker Non-Vote 19,200,437 7,879,289 1,504,082 2,715,513”
Shareholder Votes
MEDICINOVA INC shareholders approved Ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. at the 2023-06-13 meeting.
“To ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. This proposal was approved, with the votes thereon at the Annual Meeting as follows: Final Voting Results For Against Abstain Broker Non-Vote 27,807,178 2,362,900 1,129,243 -”
Shareholder Votes
MEDICINOVA INC shareholders approved Election of one Class I Director nominee named below to serve until the 2026 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until their earlier death, resignation or removal. at the 2023-06-13 meeting.
“To elect one Class I Director nominee named below to serve until the 2026 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until their earlier death, resignation or removal. The named nominee was so elected, with the votes thereon at the Annual Meeting as follows: Final Voting Results Nominees For Against Abstain Broker Non-Vote Hideki Nagao 19,685,986 7,517,392 1,380,430 2,715,513”
Jeff Himawan departed as Director at MEDICINOVA INC.
“On April 20, 2023, Jeff Himawan, Ph.D., a member of the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) notified the Board that he will not stand for re-election as a Class I director of the Company at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”) due solely to a personal decision related to health reasons.”
Douglas Paulin resigned as Chief Financial Officer at MEDICINOVA INC.
“Effective June 16, 2022, Douglas Paulin resigned as Chief Financial Officer of MediciNova, Inc.”
Douglas Paulin was appointed as Chief Financial Officer at MEDICINOVA INC.
“In addition, effective August 1, 2021, the Board appointed Douglas Paulin, CPA, of the accounting services firm Signature Analytics San Diego LLC (“Signature Analytics”) to serve as Chief Financial Officer and Principal Financial Officer of the Company.”
Edward Stepanow resigned as Chief Financial Officer at MEDICINOVA INC.
“Effective July 31, 2021, Edward Stepanow resigned as Chief Financial Officer of MediciNova, Inc. (the “Company”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.